A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD

Eugene Somoza, MD, PhD
Theresa Winhusen, PhD
Co-Lead Investigators
University of Cincinnati/CinARC

The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD.  The study involved 255 participants, recruited from six sites.
CTN-0029 Study Protocol


Prolonged abstinence rates for the OROS-MPH and placebo groups did not differ significantly.  OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated.

Primary Outcomes Article: Winhusen TM, et al. Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment on Smoking Cessation Intervention in ADHD Smokers: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychiatry 2010;71(12):1680-1688. [get article]



Publications about CTN-0029

Study data from NIDA Data Share (NCT00253747)

NIDA protocol page

Ohio Valley (Lead) search www
Maryhaven, Inc. search
Mayo Clinic search
Greater New York search www
(formerly Long Island) search www
(formerly New York) search www
New York State Psychiatric Institute search
VA New York Harbor Healthcare System search
New England Consortium search www
(formerly Northern New England) search www
MGH Pediatric Psychopharmacology search
Western States search www
(formerly Oregon/Hawaii) search www
Kaiser Permanente (Center for Health Research) search

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 2/2011 --